TSRL, Inc Presents at the 28th International Conference on Antiviral Research

Ann Arbor, Michigan, May 14th, 2015: TSRL Inc., a pharmaceutical company developing novel anti-infective therapeutics in areas of high unmet medical need, is pleased to announce that Elke Lipka, PhD, MBA, has presented at the 28th International Conference on Antiviral Research (ICAR) in Rome, Italy. The presentation, entitled "Potent Broad Spectrum Anti-DNA Viral Activity for HPMPA and HPMPC Tyrosinamide Prodrugs", reports on the broad spectrum antiviral activity of acyclic nucleoside phosphonates (ANPs) as useful agents in the treatment of many DNA virus infections.

The full poster presentation can be accessed here.

About TSRL, Inc.

TSRL, Inc. is a privately-held anti-infectives drug development firm and accelerator focused on R&D efforts to optimize effectiveness and safety of investigational and marketed therapeutics. More information about TSRL, Inc. is available on the company website www.tsrlinc.com or can be requested by contacting Dr. Elke Lipka, President, 734 663-4233 x236, elipka@tsrlinc.com.

TSRL, Inc. Announces Appointment of President

Ann Arbor, Michigan, September 11th, 2014: Therapeutic Systems Research Laboratories, (TSRL), Inc. is pleased to announce the appointment of Dr. Elke Lipka as President of TSRL and Member of the Board of Directors. Dr. Lipka succeeds the late Dr. John Hilfinger, who led the company over the past ten years, transitioning its focus from formulation development to prodrug design and delivery. Dr. Lipka, who has served as Vice President of Business Development since 2007, has played a pivotal role in the development of TSRL’s existing assets and the evaluation of new project and growth opportunities. She is an experienced drug development professional with 20 year of experience in the pharmaceutical industry including at Warner-Lambert, Esperion Therapeutics and Pfizer. Dr. Lipka holds a PhD from Goethe University, Frankfurt, Germany and an MBA from the University of Michigan.

TSRL, Inc. is a privately held oral drug delivery specialty firm focused on R&D efforts to enhance the targeted delivery of investigational and marketed therapeutics. More detailed information about TSRL is available on the company website www.tsrlinc.com or can be requested by contacting Dr. Elke Lipka, President, 734 663-4233 x236, elipka@tsrlinc.com.

TSRL Announces Receipt of $4.2 Million in New SBIR Funding

Ann Arbor, Michigan, June 24th, 2014: Therapeutic Systems Research Laboratories, Inc. (TSRL), announced today that the company was awarded two Phase I and one Phase II Small Business Innovation Research (SBIR) grants from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The grants are supporting the preclinical research of the company’s broad-spectrum antiviral prodrug program, as well as the development of an antiviral therapeutic for the treatment of adenovirus infections. TSRL will be receiving up to $4.2 million over the next 3 years through these SBIR grants. In addition, initial manufacturing scale up of a lead candidate and preclinical pharmacology testing has been performed for TSRL by NIAID under the NIAID preclinical services contracts program.

TSRL, Inc. is a privately held oral drug delivery specialty firm focused on R&D efforts to enhance the targeted delivery of investigational and marketed therapeutics. More detailed information about TSRL is available on the company website www.tsrlinc.com or can be requested by contacting Dr. Elke Lipka, Vice President for Business Development, 734 663-4233 x236, elipka@tsrlinc.com.

TSRL, Inc. Announces Agreement with Software Licensee

Ann Arbor, Michigan, June 12th, 2014: Therapeutic Systems Research Laboratories, (TSRL), Inc. announced today that it has entered into a Termination and Non-Assertion Agreement (the “Agreement”) with Simulations Plus, Inc., a California corporation (“SLP”). Under the terms of the Agreement, SLP and TSRL agreed to terminate the Exclusive Software Licensing Agreement, under which TSRL licensed to SLP Software Technology and Databases in return for royalty payments. SLP will pay TSRL a total consideration of $6 million.

TSRL, Inc. is a privately held oral drug delivery specialty firm focused on R&D efforts to enhance the targeted delivery of investigational and marketed therapeutics. More detailed information about TSRL is available on the company website www.tsrlinc.com or can be requested by contacting Dr. Elke Lipka, Vice President of Business Development, 734 663-4233 x236, elipka@tsrlinc.com.